Files and links (2)
Published, Version of Record (VoR)Open Access (License Unspecified), Open
Journal article
Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids
Journal of virology, v 87(12), pp 6931-6942
01 Jun 2013
PMID: 23576513
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Chronic hepatitis B virus (HBV) infection, a serious public health problem leading to cirrhosis and hepatocellular carcinoma, is currently treated with either pegylated alpha interferon (pegIFN-α) or one of the five nucleos(t)ide analogue viral DNA polymerase inhibitors. However, neither pegIFN-α nor nucleos(t)ide analogues are capable of reliably curing the viral infection. In order to develop novel antiviral drugs against HBV, we established a cell-based screening assay by using an immortalized mouse hepatocyte-derived stable cell line supporting a high level of HBV replication in a tetracycline-inducible manner. Screening of a library consisting of 26,900 small molecules led to the discovery of a series of sulfamoylbenzamide (SBA) derivatives that significantly reduced the amount of cytoplasmic HBV DNA. Structure-activity relationship studies have thus far identified a group of fluorine-substituted SBAs with submicromolar antiviral activity against HBV in human hepatoma cells. Mechanistic analyses reveal that the compounds dose dependently inhibit the formation of pregenomic RNA (pgRNA)-containing nucleocapsids of HBV but not other animal hepadnaviruses, such as woodchuck hepatitis virus (WHV) and duck hepatitis B virus (DHBV). Moreover, heterologous genetic complementation studies of capsid protein, DNA polymerase, and pgRNA between HBV and WHV suggest that HBV capsid protein confers sensitivity to the SBAs. In summary, SBAs represent a novel chemical entity with superior activity and a unique antiviral mechanism and are thus warranted for further development as novel antiviral therapeutics for the treatment of chronic hepatitis B.
Metrics
Details
- Title
- Sulfamoylbenzamide Derivatives Inhibit the Assembly of Hepatitis B Virus Nucleocapsids
- Creators
- Matthew R. Campagna - Drexel UniversityFei Liu - Drexel UniversityRicheng Mao - Hepatitis B FoundationCourtney Mills - Hepatitis B FoundationDawei Cai - Drexel UniversityFang Guo - Drexel UniversityXuesen Zhao - Department of Microbiology and Immunology, Drexel University College of MedicineHong Ye - Hepatitis B FoundationAndrea Cuconati - Hepatitis B FoundationHaitao Guo - Drexel UniversityJinhong Chang - Drexel UniversityXiaodong Xu - Hepatitis B FoundationTimothy M. Block - Drexel UniversityJu-Tao Guo - Drexel University
- Publication Details
- Journal of virology, v 87(12), pp 6931-6942
- Publisher
- American Society for Microbiology
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Microbiology and Immunology
- Web of Science ID
- WOS:000319508600037
- Scopus ID
- 2-s2.0-84878588315
- Other Identifier
- 991019168790004721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Virology